Valsartan Dosing Guidelines

Introduction to Valsartan Dosing

The American College of Cardiology recommends a target dose of valsartan for hypertension of 160 mg twice daily (320 mg total daily dose) for heart failure patients, though for uncomplicated hypertension the FDA-approved maximum is 320 mg once daily 1, 2

For heart failure with reduced ejection fraction (HFrEF), the target dose is 160 mg twice daily (320 mg total daily), which represents the maximum dose studied in clinical trials 1
The American College of Cardiology suggests that in the VALIANT trial, the target dose was 160 mg twice daily (320 mg total daily) for post-MI patients with LV dysfunction, demonstrating equivalence to captopril in reducing mortality 3

No specific dose adjustment is provided in the FDA labeling for patients with renal impairment, though caution is advised when creatinine levels are high or eGFR is low, according to Praxis Medical Insights 4
The European Heart Journal advises against combining valsartan with an ACE inhibitor, as this increases the risk of hyperkalemia and renal dysfunction 5, 4

Monitoring for hypotension, renal impairment, and hyperkalemia is necessary, especially when initiating therapy or increasing doses, as recommended by Praxis Medical Insights 4
Significant hyperkalemia requires caution and specialist advice, with monitoring of potassium within 1-2 weeks after initiation or dose increases, according to Praxis Medical Insights 4
The European Heart Journal recommends avoiding NSAIDs unless essential, as they may attenuate diuretic effects and cause renal impairment 4